Pyrazoline CB1b Antagonists for CNS-Sparing Obesity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CB1 receptor blockers for obesity treatment cause significant CNS adverse side effects due to non-selective targeting of brain and peripheral tissues, limiting their therapeutic efficacy and safety.
Innovation Solution
Development of novel pyrazoline compounds that selectively target CB1b receptors in peripheral tissues such as adipose tissue, liver, muscle, pancreas, and gastrointestinal tract, while sparing CB1 receptors in the brain, thereby reducing CNS adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective CB1 receptor blockers are used to treat obesity, then appetite suppression and weight reduction are achieved, but psychiatric and neurological side effects occur due to blockade of brain CB1 receptors
Solution Approach 1:
The patent applies local quality by creating compounds with differential tissue distribution properties. The compounds are designed to have high affinity for CB1b receptors in peripheral tissues (adipose tissue, liver, muscle, pancreas) while having limited penetration into the brain, thereby achieving selective action in specific locations rather than uniformly across all CB1 receptor sites
Solution Approach 2:
The patent segments the CB1 receptor system into two distinct populations: CB1a receptors in the brain and CB1b receptors in peripheral tissues. By developing compounds that selectively target CB1b receptors, the invention separates the therapeutic effects (mediated by peripheral CB1b blockade) from the adverse effects (mediated by brain CB1a blockade), allowing independent optimization of each
2Productivity
If CB1 receptor blockers are used at efficacious doses for weight reduction, then appetite suppression is achieved, but the same doses produce pronounced psychiatric and neurological side effects
Solution Approach 1:
The compounds are engineered with molecular structures that favor accumulation in peripheral tissues over the brain. This is achieved through specific structural features that enhance lipophilicity and tissue penetration in peripheral organs while limiting blood-brain barrier crossing, thereby concentrating the pharmacological effect where it is therapeutically beneficial
Solution Approach 2:
The patent introduces a selective CB1b receptor binding mechanism as an intermediary step between drug administration and therapeutic effect. This selective binding acts as a mediator that directs the drug's action primarily to peripheral tissues, preventing direct interaction with brain CB1 receptors and thus decoupling therapeutic efficacy from adverse effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively treat obesity and related disorders like diabetes, cardiometabolic diseases, and inflammation with reduced psychiatric and neurological side effects, offering improved therapeutic benefits.
Implementation Method 1
novel pyrazoline compounds that selectively target CB1b receptors in peripheral tissues
Data Source
AI summary
Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbidities thereof. Also disclosed are compositions containing one or more of the compounds and uses of the compounds in the treatment of disorders in a subject.